Amivantamab-vmjw Injection
Amivantamab-vmjw injection is used to treat a certain type of non-small cell lung cancer (NSCLC) that spread to other parts of the body or cannot be removed by surgery, and has worsened either during or after treatment with platinum chemotherapy medications. Amivantamab-vmjw injection is in a class of medications called bispecific antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
🔔 How should this medicine be used?
Amivantamab-vmjw injection comes as a solution (liquid) to be injected slowly into a vein by a doctor or nurse in a medical facility or infusion center. Initially, it is usually given once a day for 2 days in a row. After the initial 2 doses, it is usually given once every 2 weeks for as long as your treatment continues. The length of treatment depends on how well your body responds to the medication and the side effects that you experience.
A doctor or nurse will watch you closely while you are receiving the infusion and after the infusion to be sure you are not having a serious reaction to the medication. You may be given other medications to help prevent reactions to amivantamab-vmjw. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during the infusion: nausea, shortness of breath, fever, chills, flushing, chest pain, lightheadedness, nausea, or vomiting.
Your doctor may need to slow down your infusion, or interrupt or stop your treatment if you experience certain side effects. Talk to your doctor about how you are feeling during and after your treatment.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
🔔 Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
The per capita price of healthcare per year is higher in the United States than in any other nation in the world, according to National Public Radio (NPR). America spends nearly 2.5 times as much per person as the United Kingdom does, despite having comparable wealth and a lower life expectancy.
